New Jersey 2026-2027 Regular Session

New Jersey Assembly Bill AR69

Introduced
1/13/26  

Caption

Urges NJ DOH to increase public awareness on effects of xylazine.

Impact

If enacted, AR69 would not create new regulations but would urge the New Jersey Department of Health to enhance its educational efforts related to xylazine. It aims to inform the public of the risks associated with xylazine use, especially in combination with other central nervous system depressants such as opioids and alcohol. By addressing the scope of xylazine-related health threats, the resolution signifies a proactive approach in New Jersey's strategy to manage substance-related public health issues.

Summary

Assembly Resolution AR69 seeks to address the growing public health concern surrounding the use of xylazine, also known as 'Tranq' or 'Zombie Drug', in New Jersey. This non-opioid, veterinary tranquilizer, not approved for human use, has been linked to increasing overdose deaths in humans. With its dangerous effects on the central nervous system, such as causing drowsiness, amnesia, and dangerously low heart rates, there is significant impetus for raising public awareness about the drug’s risks. The bill underscores the need for educational resources that inform New Jerseyans about these dangers and promote public health safety.

Contention

While the bill does not outline specific legislative changes, the urgency for raising awareness reflects ongoing debates in public health discussions regarding drug misuse and dependency. Some stakeholders may view this resolution as a necessary step towards combating the opioid crisis, while others may argue about the adequacy of education versus enforcement measures in addressing drug-related harms. Notably, there is concern regarding the limitations of current overdose treatments, as naloxone cannot counteract xylazine overdoses, which adds a layer of complexity to the public health response.

Notable_points

The resolution highlights not only the dangers of xylazine but also stresses its widespread misuse, particularly in combination with fentanyl. The document emphasizes that repeated use can cause severe physical complications alongside mortality risk, thereby framing the discussion around the broader implications for community health initiatives. The bill’s sponsors and co-sponsors, representing various districts, demonstrate a bipartisan commitment to tackling public health crises in New Jersey.

Companion Bills

NJ SR12

Carry Over Urges NJ DOH to increase public awareness on effects of xylazine.

NJ AR82

Carry Over Urges NJ DOH to increase public awareness on effects of xylazine.

NJ SR38

Same As Urges NJ DOH to increase public awareness on effects of xylazine.

Similar Bills

No similar bills found.